A combination shot for flu and COVID-19 using messenger RNA generated antibodies in a company-funded study.

Moderna says its COVID-19 vaccine works in babies, toddlers and preschoolers.

Moderna is scaling back expectations for the number of COVID-19 vaccine deliveries it expects to make this year and the revenue it will record from them.

The director of the National Institutes of Health is warning of tough days ahead amid surging COVID-19 infections.

Moderna President Dr. Stephen Hoge says his company is working on developing COVID-19 vaccine booster shots while also trying to harness the genetic code technology it helped pioneer to fight other diseases.

Moderna said its vaccine appears to be 94.5% effective, according to preliminary data from an ongoing study. Moderna’s vaccine is being studied in 30,000 volunteers who received either the real thing or a dummy shot. Moderna’s vaccine also starts off frozen, but the company said Monday it can be thawed and kept in a regular refrigerator for 30 days, easing that concern. Both Moderna's shots and the Pfizer-BioNTech candidate are so-called mRNA vaccines, a brand-new technology. Instead, the vaccine contains a piece of genetic code that trains the immune system to recognize the spiked protein on the surface of the virus.

______NEW BRUNSWICK, N.J. — Johnson & Johnson has begun a new late-stage trial of its experimental COVID-19 vaccine, this time on a two-dose regimen. J&J plans to give up to 30,000 people two doses of the vaccine. A small, early-stage study of the vaccine found it triggered a strong immune response and was well tolerated. Gavin Newsom said he was pulling the “emergency brake” Monday on the state’s efforts to reopen its economy as coronavirus cases surge more dramatically than during a summer spike. ___BERLIN — German Chancellor Angela Merkel said on Monday the number of new coronavirus cases is flattening following two weeks of new restrictions, but it’s too early to tell whether more will be necessary.

Asian shares rose Tuesday, after the Dow Jones Industrial Average hit a record high on optimism that a vaccine may soon control the coronavirus and the economic destruction it’s caused. Moderna said its COVID-19 vaccine appears to be 94.5% effective, according to preliminary data. Japan's benchmark rose 0.2% to 25,968.22 in morning trading, after momentarily reaching a 29-year high of above 26,000. “Asia-Pacific markets continue to bask under the vaccine glow.”Even as a fresh surge of COVID-19 infections hit Japan, the economy marked a rebound in the third quarter. For 2021, Fitch projects a return to 2.7% growth in 2021, which is better than its earlier forecast for 2.1% growth.